175 related articles for article (PubMed ID: 8612303)
1. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies.
Webber S; Bartlett CA; Boritzki TJ; Hillard JA; Howland EF; Johnston AL; Kosa M; Margosiak SA; Morse CA; Shetty BV
Cancer Chemother Pharmacol; 1996; 37(6):509-17. PubMed ID: 8612303
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC
Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922
[TBL] [Abstract][Full Text] [Related]
3. 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
Wells P; Aboagye E; Gunn RN; Osman S; Boddy AV; Taylor GA; Rafi I; Hughes AN; Calvert AH; Price PM; Newell DR
J Natl Cancer Inst; 2003 May; 95(9):675-82. PubMed ID: 12734319
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the effect of AG337, a novel lipophilic thymidylate synthase inhibitor, on human head and neck and human leukemia cell lines.
McGuire JJ; Canestrari JG; Nagel GS
Int J Oncol; 1999 Dec; 15(6):1245-50. PubMed ID: 10568835
[TBL] [Abstract][Full Text] [Related]
5. The potentiation of radiation response in human colon carcinoma cells in vitro and murine lymphoma in vivo by AG337 (Thymitaq), a novel thymidylate synthase inhibitor.
Kim SH; Brown SL; Kim JH
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):789-93. PubMed ID: 9845097
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
[TBL] [Abstract][Full Text] [Related]
7. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
8. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
9. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
10. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
Backus HH; Pinedo HM; Wouters D; Kuiper CM; Jansen G; van Groeningen CJ; Peters GJ
Oncol Res; 2000; 12(5):231-9. PubMed ID: 11417748
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
12. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
13. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells.
Aherne GW; Hardcastle A; Raynaud F; Jackman AL
Biochem Pharmacol; 1996 May; 51(10):1293-301. PubMed ID: 8787544
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibition of thymidylate synthase by two series of nonclassical quinazolines.
McNamara DJ; Berman EM; Fry DW; Werbel LM
J Med Chem; 1990 Jul; 33(7):2045-51. PubMed ID: 2362285
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
17. Quinazoline antifolates thymidylate synthase inhibitors: lipophilic analogues with modification to the C2-methyl substituent.
Hennequin LF; Boyle FT; Wardleworth JM; Marsham PR; Kimbell R; Jackman AL
J Med Chem; 1996 Feb; 39(3):695-704. PubMed ID: 8576912
[TBL] [Abstract][Full Text] [Related]
18. Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series.
Marsham PR; Jackman AL; Barker AJ; Boyle FT; Pegg SJ; Wardleworth JM; Kimbell R; O'Connor BM; Calvert AH; Hughes LR
J Med Chem; 1995 Mar; 38(6):994-1004. PubMed ID: 7699716
[TBL] [Abstract][Full Text] [Related]
19. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action.
Skelton LA; Ormerod MG; Titley JC; Jackman AL
Cytometry; 1998 Sep; 33(1):56-66. PubMed ID: 9725559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
